Clinical Trials Browser

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03943901 2026-01-29

Split-Dose R-CHOP for Older Adults With DLBCL

Phase 2 Active not recruiting

27 enrolled 11 charts

Lymphoid

Lymphoma, Neoplasms, Lymphoma, Large B-Cell, Diffuse

NCT01046825 2025-12-10

Mature B-Cell Lymphoma And Leukemia Study III

Phase 2/3 Active not recruiting

128 enrolled 12 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Lymphoma, Non-Hodgkin

NCT03907488 2025-12-04

Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma

Phase 3 Active not recruiting

994 enrolled 11 charts

Lymphoid

Hodgkin Disease

NCT02369458 2025-11-18

Mitomycin C in Patients With Incurable p16 Positive Oropharyngeal and p16 Negative Head and Neck Squamous Cell Carcinoma (HNSCC) Resistant to Standard Therapies

Phase 2 Completed

48 enrolled 12 charts

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT04383743 2025-09-18

Pembrolizumab and Combination Chemotherapy Before Surgery for the Treatment of Muscle-Invasive Bladder Cancer

Phase 2 Completed

17 enrolled 12 charts

Genitourinary

Urinary Bladder Neoplasms

NCT03107988 2025-09-15

NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922)

Phase 1 Completed

65 enrolled 38 charts

CNS

Neuroblastoma

NCT00911183 2025-08-29

FRAIL-06

Phase 2 Completed

67 enrolled 11 charts

Lymphoid

Lymphoma, Lymphoma, Large B-Cell, Diffuse

NCT03646123 2025-08-28

Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma

Phase 2 Terminated

255 enrolled 29 charts

Lymphoid

Hodgkin Disease

NCT00334815 2025-08-24

Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery

Phase 2 Active not recruiting

29 enrolled 10 charts

Thoracic

Adenocarcinoma of Lung, Adenocarcinoma, Bronchiolo-Alveolar

NCT05032183 2025-08-11

Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Phase 1/2 Terminated

4 enrolled 8 charts

LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT00070564 2025-07-31

S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer

Phase 3 Active not recruiting

3,294 enrolled 22 charts

Breast

Breast Neoplasms, Breast Neoplasms, Male

NCT01437488 2025-05-04

Cabazitaxel in Patients With Urothelial Carcinoma Who Have Disease Progression Following Platinum-Based Chemotherapy

Phase 2 Completed

14 enrolled 12 charts

Genitourinary

Carcinoma, Transitional Cell

Clinical Trials

Neoadjuvant Carbo/Paclitaxel Followed by Doxorubicin/Cyclophosphamide in Breast Cancer

Split-Dose R-CHOP for Older Adults With DLBCL

Mature B-Cell Lymphoma And Leukemia Study III

Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma

Mitomycin C in Patients With Incurable p16 Positive Oropharyngeal and p16 Negative Head and Neck Squamous Cell Carcinoma (HNSCC) Resistant to Standard Therapies

Pembrolizumab and Combination Chemotherapy Before Surgery for the Treatment of Muscle-Invasive Bladder Cancer

NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922)

FRAIL-06

Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma

Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery

Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer

Cabazitaxel in Patients With Urothelial Carcinoma Who Have Disease Progression Following Platinum-Based Chemotherapy